ITGAX and hepatocellular carcinoma: 172). However, it is important to consider that MyD88's involvement in TAMs may differ, resulting in M1 or M2 polarization in various situations. MyD88 may have a role in the development of pro-tumour immunity, since therapy with its inhibitor, TJ-M2010-5, resulted in an increase in anti-tumour M1 macrophages (F4/80 CD11c) in the TME and lowered HCC growth (Ref. 172).